Certain embodiments disclosed herein relate generally to a medical balloon. Particular embodiments disclose features of a medical balloon such as an angioplasty balloon having adjustable outer dimensions, controlled cone angles, and methods of controlled tearing of plaque during an angioplasty procedure.
Atherosclerotic occlusive disease is the primary cause of stroke, heart attack, limb loss, and death in the United States and the industrialized world. Atherosclerotic plaque forms a layer along the wall of an artery and is comprised of calcium, cholesterol, compacted thrombus and cellular debris. As the atherosclerotic disease progresses, the blood supply intended to pass through a specific blood vessel is diminished or even prevented by the occlusive process. One of the most widely utilized methods of treating clinically significant atherosclerotic plaque is balloon angioplasty.
Balloon angioplasty is a method of opening blocked or narrowed blood vessels in the body. The balloon angioplasty catheter is placed into the artery from a remote access site that is created either percutaneously or through open exposure of the artery. The catheter is typically passed along the inside of the blood vessel over a wire that guides the way of the catheter. A portion of the catheter with a balloon attached is placed at the location of the atherosclerotic plaque that requires treatment. The balloon is inflated, generally to a size consistent with the original diameter of the artery prior to developing occlusive disease.
When the balloon is inflated, the plaque may be stretched, compressed, fractured, and/or broken, depending on its composition, location, and the amount of pressure exerted by the balloon. Plaque can be heterogeneous and may be soft in some areas or hard in others, causing unpredictable cleavage planes to form under standard balloon angioplasty. Balloon angioplasty can cause plaque disruption and sometimes arterial injury at the angioplasty site. There is a continuing need to improve the methods and systems for treating occlusive disease, including balloon angioplasty methods and systems.
According to some embodiments, a medical balloon system can have an adjustable outer diameter. The medical balloon system can comprise an elongated shaft defining a longitudinal axis; a medical balloon on a distal end of the elongated shaft; and a control system. The control system can have a plurality of longitudinally extending members, each of the longitudinally extending members positioned along a surface of the medical balloon, the plurality of longitudinally extending members having at least two positions with respect to the elongated shaft to thereby control an outer diameter of the medical balloon. In at least one of the at least two positions when the medical balloon is in an expanded state the medical balloon can comprise a plurality of lobes, each lobe of the plurality of lobes being formed because of and between two longitudinally extending members of the plurality of longitudinally extending members; and the position of the plurality of longitudinally extending members with respect to the elongated shaft can control the maximum outer diameter of the medical balloon when the medical balloon is expanded.
The balloon can be a drug eluting balloon. In addition, each of the longitudinally extending members of the plurality of longitudinally extending members can comprise a plurality of protrusions configured to serrate plaque in a blood vessel.
A treatment method can include a number of steps such as: 1) advancing a medical balloon to a treatment location in a vessel having a narrowed diameter, the medical balloon having a cage positioned on an outside surface of the medical balloon, the cage and medical balloon both being in a collapsed state; 2) expanding the cage from the collapsed state to a first expanded state to serrate plaque at the treatment location, the cage having a plurality of longitudinally extending members each having protrusions located along a length of the longitudinally extending member, the protrusions configured to serrate plaque; 3) partially collapsing the cage to limit a maximum outer diameter of the medical balloon; and 4) expanding the medical balloon at the treatment location to expand the vessel, the expansion being limited by the cage and thereby creating lobes of the medical balloon on either side of each of the plurality of longitudinally extending members of the cage.
In some treatment methods expanding the medical balloon can further comprise exposing a drug coating on the medical balloon that can been positioned in folds in the balloon adjacent the longitudinal extending members.
A medical balloon system can provide controlled drug delivery to a vessel. Embodiments of the medical balloon system can comprise an elongated shaft defining a longitudinal axis; a medical balloon on a distal end of the elongated shaft; a plurality of longitudinally extending members, each of the longitudinally extending members positioned along a surface of the medical balloon; and a drug coating positioned on only select areas of an outer surface of the medical balloon. In a first state the medical balloon can comprise a first plurality of lobes, the balloon having a first outer surface and folds that create the lobes, the drug coating being completely positioned within the folds in the first state and thereby not being exposed to fluid flow in a vessel, each of the longitudinally extending members positioned along the first outer surface. In a second state the medical balloon is expanded from the first state and the medical balloon can comprise a second plurality of lobes wherein the drug coating in the folds of the first plurality of lobes now defines at least a portion of a second outer surface and the first outer surface of the first plurality of lobes is inward from the second outer surface, each lobe of the second plurality of lobes being formed because of and between two longitudinally extending members of the plurality of longitudinally extending members.
In some embodiments, the medical balloon can further comprise an adhesive that seals the folds of the first plurality of lobes to prevent premature exposure of the drug coating. Further, each of the longitudinally extending members can have protrusions located along a length of the longitudinally extending member, the protrusions configured to serrate plaque.
Another treatment method can include the steps of: 1) advancing a medical balloon to a treatment location in a vessel having a narrowed diameter, the medical balloon having a cage positioned along a surface of the medical balloon, the cage and medical balloon both being in a collapsed state, the cage having a plurality of longitudinally extending members; 2) expanding the medical balloon to a first state wherein the medical balloon comprises a first plurality of lobes, the balloon having a first outer surface and folds that create the lobes, a drug coating positioned within the folds in the first state and thereby not being exposed to fluid flow in the vessel, each of the longitudinally extending members positioned along the first outer surface; 3) expanding the medical balloon to a second state larger than the first wherein the medical balloon comprises a second plurality of lobes wherein the drug coating in the folds of the first plurality of lobes defines at least a portion of a second outer surface and the first outer surface of the first plurality of lobes is inward from the second outer surface, each lobe of the second plurality of lobes being formed because of and between two longitudinally extending members of the plurality of longitudinally extending members; and 4) exposing the treatment location in the vessel to the drug coating.
Various embodiments are depicted in the accompanying drawings for illustrative purposes, and should in no way be interpreted as limiting the scope of the inventions, in which like reference characters denote corresponding features consistently throughout similar embodiments.
Disclosed herein are various embodiments of systems and methods discussed primarily in the context of treating occlusive disease, including balloon angioplasty methods and systems. At the same time, it will be understood that the concepts and principles embodied in the various embodiments can also be used with other types of medical balloons and other types of medical procedures.
An off-the-shelf medical balloon, such as an angioplasty balloon can be used to create a serration or cutting balloon. The catheter balloon can have a catheter shaft with a balloon at the distal end. Radiopaque markers can be positioned inside the balloon. The shaft can be hollow and can be used to inflate the balloon and can also be used with a guidewire. Thus, the shaft can have two channels, one for inflation and one for positioning with a guidewire. A hub can be used with two entry points for the shaft and can be a y-hub and strain relief.
In some embodiments the catheter can be a coaxial over-the-wire balloon catheter with a guidewire size compatibility of 0.018″. A high pressure (non-compliant/semi-compliant) trifold balloon can be made of nylon material with a diameter of 5 mm and a length of 20 mm±1 mm. The balloon has a nominal inflation pressure of 10 atm. a rated burst pressure of 22 atm, and an average burst pressure of 22 atm. The catheter working length is 110 cm±2 cm and has a tapered tip length of 3 mm±0.5 mm. Two standard radiopaque makers 42 are made up of 90% platinum and 10% iridium. The radiopaque markers 42 indicate the balloon working length. The inner shaft has a lubricious HDPE inner layer. The profile of the outer shaft is clear and 4.3 FR (0.056 in ±0.0008 in; 1.42 mm±0.0200 mm.
The cage 6 can be a control system that limits an outer diameter on the balloon. The cage 6 can be positioned on the outside of the balloon 4 to restrict the balloon's ability to expand. The cage 6 can be adjustable to limit expansion of the balloon in a stepwise or an infinitely adjustable manner within a certain range. In some embodiments, the cage 6 for a PTA balloon can enable balloon diameter ranges above 1 mm. In some embodiments, the cage 6 can limit expansion of the balloon independent of the pressure within the balloon. This system can offer clinicians a new range of PTA dimensions with a single device.
A cage 6 can be positioned around the balloon 4. As shown, the cage 6 is positioned outside of the balloon 4, though in some embodiments the cage 6 can be positioned inside the balloon. In some embodiments the cage 6 can be positioned between two layers of material that form the balloon. The cage 6 can include a series of longitudinally extending members 10. The longitudinally extending members 10 can be in the form of strips 10 (shown in
The cage 6 can be controlled by changing the linear distance between its two ends 12, 14 as shown in
As can be seen, in one embodiment, the longitudinally extending members 10 have been formed so as to have angled sections on either end connected by straight portions. A bend at the junction between the angled section and the straight section can be formed into the longitudinally extending members 10 to encourage them to take on this shape. Pre-forming the longitudinally extending members 10 can help control expansion of the balloon 4 in a particular manner. Other features such as material thickness and shape can also be used to control the expanded shape of the longitudinally extending members 10. As seen in
The longitudinally extending members 10 can be free floating with respect to the balloon 4, or can be attached in part or in whole to the balloon 4. For example, in one embodiment all or part of the distal angled portion of one or more of the longitudinally extending members 10 can be connected to a distal portion of the balloon 4 such as a cone shaped portion of the balloon 4. In some embodiments the longitudinally extending members 10 can be connected to the balloon 4 but able to slide or move with respect thereto (see
Looking now to
Increasing the diameter of the cage 6 by decreasing its length reduces the restrictions on movement of the outer material of the balloon 4. Thus, the outer material can expand further to increase the diameter of the balloon 4. This can be seen in
In the illustrated embodiment, when the balloon 4 is expanded, an increasing amount of pressure (typically in a hydraulic form) expands the outer diameter of the balloon 4 until the point where the cage 6 constricts further expansion. Once the desired limit of expansion of the outer diameter of the cage 6 is obtained, the operator may continue to increase the pressure of the balloon 4 up to a desired pressure. Despite the increasing pressure of the balloon 4, the cage 6 can maintain a set outer diameter. The cage 6 thereby offers a unique ability to separate the outer diameter of the balloon 4 from the typical mechanism used to expand the balloon 4 (namely pressure). The mechanism of control over the outer diameter of the cage 6 can be done by moving one or both sides of the cage 6 towards each other. As a result of the expansion or constriction of the cage 6, the material of the balloon 4 that is taut or stretched is loosened. This allows for further expansion of the balloon 4. Among other features, the range of expansion depends in large part on the size, orientation, and number of longitudinally extending members 10 that restrict the balloon 4. In some embodiments the balloon is restricted by 5 linear wires oriented longitudinally across the balloon surface and the wires are thin enough to be relatively non-obtrusive. Other types of longitudinally extending members can also be used. As an example: the diameter of a balloon can be controlled within a range of 1.125-6.000 mm, 1.50-6.00 mm, 1.75-6.0 mm, 2.0-6.0 mm. etc. for a 6 mm outer diameter balloon. The cage 6 can control the diameter of the balloon 4 up to and within a range of 3-4 times, 2-5 times, or more from the initial expanded position to the fully expanded position. In some embodiments the range can be adjusted with accuracies of tenths to thousands of a mm.
Typically, the distal end of the cage 6 will be fixed, bonded, sealed, braided, wrapped, or crimped to the balloon 4 carrying catheter. The other end of the cage can be attached, bonded, sealed, braided, wrapped, or crimped to a functional component, such as the band 14 discussed above. In some embodiments, the functional component can be precisely positioned relative to the fixed end. As the position of the functional component is shifted towards the fixed side, the longitudinally extending members 10 expand outward. In its initial position, the longitudinally extending members 10 are stretched and lay in a generally flat or parallel configuration on the outer most surface of the balloon. The initial position of the longitudinally extending members 10 can be subject to many factors including the thickness of the balloon material.
In some embodiments, as the longitudinally extending members 10 expand, they bow outward towards the wall of the blood vessel. In some embodiments, moving the two ends of the cage closer together releases tension on the longitudinally extending members 10. Expansion of the balloon then enables the functional diameter of the balloon to increase.
As has been mentioned, the longitudinally extending members 10 can be positioned in the creases of the folds of the balloon when the balloon is in an expanded state. This provides the balloon with the ability to expand uniformly in the areas between the longitudinally extending members 10 and limits the energy imparted on the longitudinally extending members 10 when the longitudinally extending members 10 are in the fully expanded state.
In some embodiments, the longitudinally extending members 10 can be positioned completely outside the balloon 4 and can define an outer diameter of the device. As the balloon expands it may expand into the cage 6 or with the cage 6. In such embodiments, there preferably would not be separate lobes, but rather the balloon as whole would expand within the cage to the outer limit defined by the cage.
The controlled and staged expansion of the cage 6 can also provide for the controlled and uniform expansion of the balloon 4 along its length. A problem frequently faced in balloon angioplasty is the uneven expansion of the angioplasty balloon—termed “dog boning.” Dog boning occurs when, at the treatment site, the proximal and distal ends of the balloon expand more than the center of the balloon—likened to a dog bone. Dog boning reduces the effectiveness of balloon angioplasty as it reduces the effective diameter of the balloon 4 at the site of treatment. The structure of the cage 6 can help ensure the uniform expansion of the balloon 4 along its length. Further, the cage 6 provides the ability to incrementally increase the diameter of the balloon 4 which, in turn, allows the treatment site to expand in an incremental and controlled manner.
Turning now to
In some embodiments, some of the filaments may also form the longitudinally extending members 10 of the cage 6. These longitudinally extending members 10 may be fixed with respect to the proximal hub or adjustable. In this way, the working length of the cage 6 and therefor of the balloon can be adjusted independent of the pressure of the balloon.
In some embodiments, the catheter is packaged with a pre-determined length of filament. This can preferably include a small amount of extra filament to provide enough length so as to not bind the balloon as the catheter migrates through the anatomy. In use within the body, the catheter may encounter various anatomical tortuosities. Once the catheter is positioned at the treatment location, the operator control mechanism (OCM) may be manipulated by the operator. In some embodiments, the OCM can be used initially to tighten each individual filament relative to the proximal hub and/or distal hub of the cage, depending on the embodiment. This tightening allows the system to accommcidate for the unknown tortuosity of the vessel. The filaments can be adjusted individually and/or collectively once the system is in the desired location. This allows the system to adapt to conditions where one filament is on the inside of the small radius of curvature while other filaments have a slightly larger radius of curvature. There can be a one to one correlation between the operator control mechanism (OCM) and the proximal and/or distal hub of the cage. When the OCM is tightened, the filaments can limit the balloon diameter. In addition, if some of the filaments cross the balloon to collectively form the cage, this may also limit the balloon diameter and/or length. In contrast, loosening the OCM and inflating the balloon, loosens the filaments allowing for controlled expansion to larger balloon diameters and/or lengths.
In
Independent of the control system and OCM used, the balloon diameter can be allowed to expand over a range of diameters with a predetermined rate of expansion. This can be done by controlling tension in the OCM to allow for slow or predetermined rates of expansion until a set point of balloon diameter is reached.
In addition, or alternatively, as shown in
In an alternate configuration shown in
Turning now to
In other embodiments, the filaments can run along groves molded into the surface of the balloon (one representative groove and filament shown in
In some embodiments the balloon can be a drug eluting balloon (“DEB”). The DEB can have longitudinally extending members 10 positioned between the folds of the balloon 4 creating lobes 8 (
In some embodiments, the lobes can be secured together, such as with adhesive to further prevent the drug coating from becoming prematurely exposed to the vessel. Expansion of the balloon can break the seal created by the adhesive to then treat the desired area with the drug.
In some embodiments the longitudinally extending members 10 are positioned on the outside of the folds 22 of the balloon 4 (
Once the DEB has reached the diseased site, the balloon 4 can be inflated to a diameter that is less than the diameter of the surface of the disease and then slowly inflated to the desired diameter. As the balloon 4 inflates beyond the initial diameter, the drug coating can become exposed and can be effectively delivered to the diseased site. By limiting the surface area of the balloon 4 with drug coating, the cage 6 can enable a greater level of control and drug retention until a point in time when release of the drug through contact is desired.
In some embodiments, the protrusions 16 are provided with a drug coating. Similarly, in some embodiments, the longitudinal extending members 10 are provided with a drug coating.
For the drug coated section, the following approach to coating of a balloon may be used. The surface of the balloon can be altered to produce a surface roughness or topographic match to the drug with predetermined, controlled and optimized geometries. The known geometry or roughness is uniquely designed to match the drug coding. The method used to enhance the surface roughness can be either additive or subtractive in nature, such as Nano-technology structures coated where desired or oblate from the surface or move materials around the surface using technology such as ultrasonics. This design offers a unique advantage to drug coatings such as limiting or reduce drug dilution or sloughing off as the balloon moves through a tortuous anatomy to the site of disease. The surface can also be optimized to enable sections of the balloon to have high drug adhesion like properties and other sections to have poor or low drug adhesion like properties. Therefore sections can be designed as drug-phobic and other sections to be drug-philic. When dipped sprayed or otherwise coated with drugs the balloon is quadrantly drug coated by design.
In some embodiments, in addition to controlling the diameter of the balloon 4, the medical balloon system 100 can also control the length of the balloon 4. For example, an outer sheath can be used to control the exposed balloon length, and the sheath can prevent the remainder of the balloon 4 from expanding. In some embodiments, the cage 6 can be constructed of a shape memory alloy with tension wires attached to band 14. In this embodiment, release of individual tension wires can allow for expansion of the cage 6 to a predetermined outer diameter.
According to some embodiments, a medical balloon system 100 can include a control system or cage 6 to control an adjustable outer diameter of the balloon 4. The control system can be pressure independent and can provide a stepped diameter or a continuously variable diameter within a set range. The balloon 4 can be a single balloon or a single chamber balloon, though multiple balloons or multiple chamber balloons can also be used. In some embodiments the length of the balloon 4 can also be controlled, such as with a stiff outer sheath. The cage 6 can be an outer wire frame that limits expansion of the balloon 4.
In some embodiments the balloon 4 can move between different star shaped cross sections until achieving a final fully expanded cross section. The final or intermediate cross section may be star shaped or circular. The balloon 4 can be formed in other shapes and configurations as well. In some embodiments, spikes can be positioned on the longitudinally extending members of the cage 6 between lobes 8 of the balloon 4.
Another benefit of the controlled balloon expansion system is it can allow for control of the angle of energy departed to the surface of the body lumen. According to some embodiments, this may be achieved through control of the depth of longitudinally extending members or the diameter at which the constrained balloon makes contact with the lumen wall. With a controlled depth of the longitudinally extending members, an angular depression can be generated along the lumen axis of the balloon that can apply a tangential force against the lumen wall at an angle of 45 degrees or less perpendicular to the lumen axis. At this angle the lumen tissue is susceptible to separating along the mid line of the depressed region. It can be noted that when attempting to tear a 2-D surface it is observed that an angle less than 90 degrees exists and offers greater control for predetermining the tear location and reduces the energy required to start and facilitate the continuation of a tear in the 2-D surface of many materials. When inducing expansion of arteries or other lumen tissue it is observed that the angle of energy departed at the lumen surface has an expansion effect at a similar angle to that as observed in the 2-D surface example. It has been observed that angles equal to or less than 45 degrees appear to have beneficial tearing effects on plaque in a blood vessel, although other predetermined angles may be used when tissue expansion is not the only desired effect.
First, the depth of the longitudinal extending members 10 can be set to optimize the angle or tangential energy for the tissue interface with the balloon 4. Next, the combination of the balloon 4 and the longitudinal extending members 10 is placed in the area for desired dilation and pressure is increased in the system. The combination of the balloon 4 and the longitudinal extending members 10 contacts the wall of the vessel and slowly the tension on the array of longitudinal extending members 10 is released. As the pressure is released, slight expansion of the balloon diameter occurs and tends to depart energy against the wall of the vessel. Because the longitudinal extending members 10 restrain the balloon surface and thereby generates a series of linear depressions at each longitudinal extending members 10 that are optimally aligned with the lumen axis. The force induced by the balloon expansion which is surrounded by a cage 6 and longitudinal extending members 10 is not only radial but also has a perpendicular force that is lateral to the surface of the lumen. Optimally the design leverages the radial energy for expansion of the balloon 4 to induce a portion of the energy into a perpendicular energy that promotes an expansion of the diseased tissue along the axis of the longitudinal extending members 10. This perpendicular force has the tendency to encourage a gentler and less injurious expansion of the tissue while the radial force behaves like a compression force against the lumen wall.
Although this invention has been disclosed in the context of certain preferred embodiments and examples, it will be understood by those skilled in the art that the present invention extends beyond the specifically disclosed embodiments to other alternative embodiments and/or uses of the invention and obvious modifications and equivalents thereof. In addition, while a number of variations of the invention have been shown and described in detail, other modifications, which are within the scope of this invention, will be readily apparent to those of skill in the art based upon this disclosure. It is also contemplated that various combinations or sub-combinations of the specific features and aspects of the embodiments may be made and still fall within the scope of the invention. Accordingly, it should be understood that various features and aspects of the disclosed embodiments can be combined with or substituted for one another in order to form varying modes of the disclosed invention. Thus, it is intended that the scope of the present invention herein disclosed should not be limited by the particular disclosed embodiments described above, but should be determined only by a fair reading of the claims that follow.
Similarly, this method of disclosure, is not to be interpreted as reflecting an intention that any claim require more features than are expressly recited in that claim. Rather, as the following claims reflect, inventive aspects lie in a combination of fewer than all features of any single foregoing disclosed embodiment. Thus, the claims following the Detailed Description are hereby expressly incorporated into this Detailed Description, with each claim standing on its own as a separate embodiment.
This application claims priority to U.S. Provisional App. No. 62/074,548 filed Nov. 3, 2014. All of the above application(s) is/are incorporated by reference herein in their entirety and are to be considered a part of this specification. Any and all applications for which a foreign or domestic priority claim is identified in the Application Data Sheet as filed with the present application are hereby incorporated by reference under 37 CFR 1.57.
Filing Document | Filing Date | Country | Kind |
---|---|---|---|
PCT/US2015/058874 | 11/3/2015 | WO | 00 |
Number | Date | Country | |
---|---|---|---|
62074548 | Nov 2014 | US |